Alize Pharma III SAS, of Lyon, France, an Alize Pharma group company, is presenting preclinical data at the American Society for Bone and Mineral Research meeting in Atlanta later this month showing that I-HBC1 increased bone mass in ovariectomized rats, a model of postmenopausal osteoporosis, and was more potent than parathyroid hormone.